Phase Ib/II trial of envafolimab, a novel subcutaneous singledomain anti-PD-L1 monoclonal antibody, plus lenvatinib in patients with selected advanced solid tumors

被引：0
|
作者：
Liu, T. [1 ]
Feng, Y. [1 ]
Xu, X. [1 ]
Ren, X. [2 ]
Jia, J. [3 ]
Pan, H. [4 ]
Wang, B. [5 ]
Wu, B. [6 ]
Cao, X. [7 ]
Liu, J. [8 ]
Yang, Y. [9 ]
Xiao, S. [10 ]
Qin, L. [10 ]
Zhu, D. [10 ]
Xu, S. [10 ]
Huang, W. [10 ]
机构：
[1] Fudan Univ, Zhongshan Hosp, Dept Oncol, Shanghai, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Dept Biol Therapy, Tianjin, Peoples R China
[3] Dongguan Peoples Hosp, Dept Oncol, Dongguan, Peoples R China
[4] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Sch Med, Hangzhou, Peoples R China
[5] 960th Hosp PLA Joint Logist Support Force, Dept Oncol, Jinan, Peoples R China
[6] China Med Univ, Shengjing Hosp, Dept Urol, Shenyang, Peoples R China
[7] Shanxi Med Univ, Hosp 1, Dept Urol, Taiyuan, Peoples R China
[8] Dalian Med Univ, Affiliated Hosp 1, Dept Med Oncol, Dalian, Peoples R China
[9] Kunming Med Univ, Yunnan Canc Hosp, Affiliated Hosp 3, Dept Urol, Kunming, Peoples R China
[10] 3D Med Inc, Dept Clin Dev, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2188
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1049P
引用
收藏
页码：S635 / S635
页数：1
相关论文
共 50 条
  • [21] Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib trial
    Chung, H. C.
    Arkenau, H. T.
    Wyrwicz, L.
    Oh, D. Y.
    Lee, K. W.
    Infante, J. R.
    Chin, K.
    Von Heydebreck, A.
    Kang, Y. K.
    Safran, H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S457 - S457
  • [22] Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma
    Du, Yu
    Dai, Jie
    Mao, Lili
    Wei, Xiaoting
    Bai, Xue
    Chen, Ling
    Lin, Jing
    Chi, Zhihong
    Cui, Chuanliang
    Sheng, Xinan
    Lian, Bin
    Tang, Bixia
    Wang, Xuan
    Yan, Xieqiao
    Li, Siming
    Zhou, Li
    Guo, Jun
    Chen, Yu
    Si, Lu
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (01) : 93 - 101
  • [23] Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors (vol 17, pg 861, 2020)
    Taylor, Matthew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23) : 2702 - 2702
  • [24] Safety and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced, unresectable mesothelioma: A phase IB trial
    Hassan, R.
    Thomas, A.
    Patel, M.
    Nemunaitis, J.
    Bennouna, J.
    Powderly, J.
    Taylor, M.
    Cuillerot, J. M.
    Von Heydebreck, A.
    Gulley, J. L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S639 - S639
  • [25] A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/ TGF-bRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors
    Xu, R-H.
    Huiyan, L.
    Zhao, H.
    Wei, W.
    Ma, D.
    Yin, X.
    Ni, Y.
    Wang, Y.
    Zhang, Y.
    Zhou, J.
    Pan, H.
    Niu, Z.
    Zhang, J.
    Ren, H.
    Kang, M.
    Jia, W.
    Gu, S.
    Liu, P.
    Zhang, Z.
    Wang, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S624 - S624
  • [26] A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors
    Callahan, Margaret K.
    Ott, Patrick Alexander
    Odunsi, Kunle
    Bertolini, Staphane V.
    Pan, Linda S.
    Venhaus, Ralph Rudolph
    Karakunnel, Joyson Joseph
    Hodi, F. Stephen
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.
    Desai, Jayesh
    Voskoboynik, Mark
    Markman, Ben
    Hou, Jeannie
    Zeng, Dewan
    Meniawy, Tarek
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.
    Xu, Jian-Ming
    Qin, Shukui
    Zhang, Yun
    Zhang, Yaoyue
    Jia, Ru
    Liu, Rongrui
    Zhang, Gairong
    Zhao, Chuanhua
    Lu, Ni
    Liu, Huilong
    Xu, Wenlian
    Fu, Meng
    Cao, Walt
    Lu, Haolan
    Liu, David
    Dong, Ruiping
    Wang, Xiaoxiao
    Wang, Pilin
    Xu, Ting
    Gong, John
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
    Brahmer, Julie R.
    Tykodi, Scott S.
    Chow, Laura Q. M.
    Hwu, Wen-Jen
    Topalian, Suzanne L.
    Hwu, Patrick
    Drake, Charles G.
    Camacho, Luis H.
    Kauh, John
    Odunsi, Kunle
    Pitot, Henry C.
    Hamid, Omid
    Bhatia, Shailender
    Martins, Renato
    Eaton, Keith
    Chen, Shuming
    Salay, Theresa M.
    Alaparthy, Suresh
    Grosso, Joseph F.
    Korman, Alan J.
    Parker, Susan M.
    Agrawal, Shruti
    Goldberg, Stacie M.
    Pardoll, Drew M.
    Gupta, Ashok
    Wigginton, Jon M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26): : 2455 - 2465
  • [30] A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors
    Taylor, M.
    Dutcus, C. E.
    Schmidt, E.
    Bagulho, T.
    Li, D.
    Shumaker, R.
    Rasco, D.
    ANNALS OF ONCOLOGY, 2016, 27
12345